Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/214
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSANTOS, Raul D.-
dc.contributor.authorWATERS, David D.-
dc.contributor.authorTARASENKO, Lisa-
dc.contributor.authorMESSIG, Michael-
dc.contributor.authorJUKEMA, J. Wouter-
dc.contributor.authorCHIANG, Cheng-Wen-
dc.contributor.authorFERRIERES, Jean-
dc.contributor.authorFOODY, JoAnne M.-
dc.date.accessioned2013-07-30T14:34:55Z-
dc.date.available2013-07-30T14:34:55Z-
dc.date.issued2012-
dc.identifier.citationATHEROSCLEROSIS, v.224, n.1, p.150-153, 2012-
dc.identifier.issn0021-9150-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/214-
dc.description.abstractObjective: This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study. Methods: 9955 patients >= 20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries. Results: Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with <= 200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America. Conclusions: Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients.-
dc.description.sponsorshipAnthera-
dc.description.sponsorshipCortria-
dc.description.sponsorshipGenentech-
dc.description.sponsorshipMerck/Schering-Plough-
dc.description.sponsorshipPfizer Inc.-
dc.description.sponsorshipAstellas-
dc.description.sponsorshipAstraZeneca-
dc.description.sponsorshipBiotronik-
dc.description.sponsorshipBoston Scientific-
dc.description.sponsorshipDaiichi Sankyo-
dc.description.sponsorshipLilly-
dc.description.sponsorshipGenzyme-
dc.description.sponsorshipMedtronic-
dc.description.sponsorshipOrbus Neich-
dc.description.sponsorshipNovartis-
dc.description.sponsorshipRoche-
dc.description.sponsorshipServier-
dc.description.sponsorshipSanofi Aventis-
dc.description.sponsorshipNetherlands Heart Foundation-
dc.description.sponsorshipInteruniversity Cardiology Institute of the Netherlands-
dc.description.sponsorshipEuropean Community Framework KP7 Programme-
dc.language.isoeng-
dc.publisherELSEVIER IRELAND LTD-
dc.relation.ispartofAtherosclerosis-
dc.rightsrestrictedAccess-
dc.subjectNon-HDL cholesterol-
dc.subjectLDL-cholesterol-
dc.subjectCoronary heart disease-
dc.subjectRisk factors-
dc.subjectTriglycerides-
dc.subject.otherlow-density-lipoprotein-
dc.subject.othercardiovascular-disease-
dc.subject.othertask-force-
dc.subject.otherguidelines-
dc.subject.otherrecommendations-
dc.subject.otherprevention-
dc.subject.othermanagement-
dc.subject.otherrisk-
dc.subject.otherapolipoproteins-
dc.subject.otherdyslipidemia-
dc.titleA comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2-
dc.typearticle-
dc.rights.holderCopyright ELSEVIER IRELAND LTD-
dc.identifier.doi10.1016/j.atherosclerosis.2012.06.052-
dc.identifier.pmid22818564-
dc.subject.wosPeripheral Vascular Disease-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalWATERS, David D.:San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA-
hcfmusp.author.externalTARASENKO, Lisa:Pfizer Inc, New York, NY USA-
hcfmusp.author.externalMESSIG, Michael:Pfizer Inc, New York, NY USA-
hcfmusp.author.externalJUKEMA, J. Wouter:Leiden Univ, Med Ctr, Leiden, Netherlands-
hcfmusp.author.externalCHIANG, Cheng-Wen:Cathay Gen Hosp, Taipei, Taiwan; Taipei Med Univ, Taipei, Taiwan-
hcfmusp.author.externalFERRIERES, Jean:Hop Rangueil, Toulouse, France-
hcfmusp.author.externalFOODY, JoAnne M.:Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA-
hcfmusp.description.beginpage150-
hcfmusp.description.endpage153-
hcfmusp.description.issue1-
hcfmusp.description.volume224-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000308078000024-
hcfmusp.origem.id2-s2.0-84865388510-
hcfmusp.publisher.cityCLARE-
hcfmusp.publisher.countryIRELAND-
hcfmusp.relation.referenceAlberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644-
hcfmusp.relation.referenceBaigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5-
hcfmusp.relation.referenceBlaha MJ, 2008, J CLIN LIPIDOL, V2, P267, DOI 10.1016/j.jacl.2008.06.013-
hcfmusp.relation.referenceCatapano AL, 2011, ATHEROSCLEROSIS, V217, P3, DOI 10.1016/j.atherosclerosis.2011.06.028-
hcfmusp.relation.referenceDavidson MH, 2005, AM J CARDIOL, V96, P556, DOI 10.1016/j.amjcard.2005.04.019-
hcfmusp.relation.referenceDe Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6-
hcfmusp.relation.referenceDi Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993-
hcfmusp.relation.referenceGenest J, 2003, CAN MED ASSOC J, V169, P921-
hcfmusp.relation.referenceGenest J, 2009, CAN J CARDIOL, V25, P567-
hcfmusp.relation.referenceKastelein JJP, 2008, CIRCULATION, V117, P3002, DOI 10.1161/CIRCULATIONAHA.107.713438-
hcfmusp.relation.referenceNational Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, NY TIMES 1026, V106, P3143-
hcfmusp.relation.referenceRobinson JG, 2009, J AM COLL CARDIOL, V53, P316, DOI 10.1016/j.jacc.2008.10.024-
hcfmusp.relation.referenceVirani SS, 2011, AM HEART J, V161, P1140, DOI 10.1016/j.ahj.2011.03.023-
hcfmusp.relation.referenceWaters DD, 2009, CIRCULATION, V120, P28, DOI 10.1161/CIRCULATIONAHA.108.838466-
hcfmusp.relation.referenceYusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipAstraZeneca-
hcfmusp.remissive.sponsorshipBayer-
hcfmusp.remissive.sponsorshipDaiichi-
hcfmusp.remissive.sponsorshipLilly-
hcfmusp.remissive.sponsorshipMerck-
hcfmusp.remissive.sponsorshipNovartis-
hcfmusp.remissive.sponsorshipPfizer-
hcfmusp.remissive.sponsorshipRoche-
hcfmusp.remissive.sponsorshipSanofi-Aventis-
hcfmusp.remissive.sponsorshipServier-
hcfmusp.citation.scopus35-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor


Files in This Item:
File Description SizeFormat 
art_SANTOS_A_comparison_of_non_HDL_and_LDL_cholesterol_2012_eng.pdf
  Restricted Access
publishedVersion (English)121.65 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.